A Noble Goal
End-stage renal disease is a dangerous reality for those who suffer from Lupus Nephritis (LN), despite improvements in immunosuppressive therapy in the last 20 years. Our next guest, Dr. Brad H Rovin, MD, FACP, FASN, is the first author of the manuscript “Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial.” which was recently published in Arthritis & Rheumatology. This study was a post hoc analysis of the NOBILITY trial and was conducted to assess kidney-related outcomes in patients using Obinutuzumab.